Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States

– Launch follows September 25, 2015 Licensing Agreement with a wholly-owned subsidiary of Knight Therapeutics Inc. (TSX:GUD) (“Knight”).

ORLANDO, Fla. and MONTREAL, March 22, 2016 /CNW/ — Profounda, Inc. (“Profounda”) announced today that Impavido® (miltefosine) is now…